Research Topic · Peer-Reviewed

Cancer Prognosis

Cancer prognosis is the estimation of the likely course and outcome of a malignancy, including expected survival, the probability of recurrence, and the chance of response to treatment. Distinct from diagnosis, which confirms the presence and type of disease, prognosis integrates clinical, pathological, and molecula…

Curated from this journal's research 📚 12 peer-reviewed articles cited Cited 61× across the literature 🔖 ISSN 2572-3030 🗓 Reviewed July 2026

Overview

Cancer prognosis is the estimation of the likely course and outcome of a malignancy, including expected survival, the probability of recurrence, and the chance of response to treatment. Distinct from diagnosis, which confirms the presence and type of disease, prognosis integrates clinical, pathological, and molecular information to forecast what is likely to happen and to guide management decisions. Prognostic assessment draws on factors such as tumor stage, histological grade, and the extent of spread, including lymph node metastasis, together with molecular and biomarker-based indicators. Research in this area evaluates how specific features correlate with outcome: elevated tissue microRNA expression associated with poorer survival, clinical and pathological variables in aggressive subtypes such as triple-negative breast cancer, expression-based recurrence scores, and epigenetic markers in head and neck cancer. Systemic and inflammatory indices, including blood cell ratios, are examined as accessible prognostic signals, while immune-related markers increasingly inform expectations for outcome and treatment benefit. By combining established clinicopathological staging with emerging molecular signatures, prognostic research aims to stratify patients by risk, distinguish indolent from aggressive disease, and support decisions about the intensity and type of therapy. Reliable prognosis ultimately helps tailor care to the individual, balancing potential benefit against burden and improving the relevance of treatment to each patient's likely trajectory.

Research published in this journal

12 peer-reviewed articles, ranked by relevance. Each links to its DOI.

2018

Epigenetic Biomarkers in Head and Neck Cancer 

Gupta ShilpiCorresponding author
Stem Cell and Cancer Research Lab, Amity Institute of Molecular Medicine & Stem Cell Research (AIMMSCR), Amity University Uttar Pradesh, Sector-125, Noida-201313, India.
Cancer Genetics And Biomarkers Cited by 11 doi:10.14302/issn.2572-3030.jcgb-18-2428
2019

Avant Garde Alleviation -Cancer Immunotherapy

Bajaj AnubhaCorresponding author
MD. (Pathology) Panjab University, Department of Histopathology, A.B. Diagnostics, A-1, Ring Road , Rajouri Garden, New Delhi, 110027, India.
Clinical and Diagnostic Pathology doi:10.14302/issn.2689-5773.jcdp-19-3061

How this research is being cited

The 12 articles above have been cited 61 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.

A sample of recent works citing this journal's research on Cancer Prognosis, linking to each citing work.

Editorial oversight

Curated from peer-reviewed research published in Cancer Genetics And Biomarkers (ISSN 2572-3030).

Journal editorial board
Dr. Charlie Gourley · United Kingdom Dr. Xinyu Chen · United States Dr. Guru Prasad Maiti · United States

This page summarises published research for orientation; it is not medical or professional advice.